Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.
Read the full article on WikipediaFamilial heterozygous hypercholesterolaemia Clinical criteria: Treatment Phase: Continuing treatment with this drug or switching treatment from a monoclonal antibody inhibiting proprotein coverase subtilisin kexin type 9 (PSCK9) for this PBS indication Patient must have previously received PBS-subsidised treatment with this drug for this condition; OR Patient must have previously received PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication, AND The treatment must be in conjunction with dietary therapy and exercise, AND Patient must not be receiving concomitant PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner in consultation with a specialist physician.
Non-familial hypercholesterolaemia Clinical criteria: Treatment Phase: Continuing treatment with this drug or switching treatment from a monoclonal antibody inhibiting proprotein coverase subtilisin kexin type 9 (PSCK9) for this PBS indication Patient must have previously received PBS-subsidised treatment with this drug for this condition; OR Patient must have previously received PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication, AND The treatment must be in conjunction with dietary therapy and exercise, AND Patient must not be receiving concomitant PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner in consultation with a specialist physician.
“Inclisiran is a small interfering RNA that acts as an inhibitor of an enzyme that degrades LDL receptors and thereby increases LDL levels in the blood. Since Inclisiran inhibits the degradation of receptors, it results in an increased number of receptors, and therefore LDL is removed from the blood.”
Working under the parallel aged-care framework? Aged-care equivalent →